Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kerry A Rogers

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
Clinical Advances in Hematology & Oncology : H&O|January 17, 2025
Choosing between CAR T-cell therapy and pirtobrutinib in double-refractory CLLKerry A Rogers
The Lancet. Oncology|May 31, 2024
GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemiaKerry A Rogers
Blood|November 24, 2018
Is less equal with ibrutinib dose?Kerry A Rogers
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2023
A CAPTIVATEing Analysis for Higher-Risk CLLKerry A Rogers
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2020
Collectively Answering the Venetoclax BTK Inhibitor Sequencing Question in CLLKerry A Rogers
Leukemia & Lymphoma|March 18, 2024
Pairing obinutuzumab with venetoclax in relapsed CLLKerry A Rogers, Philip A Thompson
Cancer Cell|January 15, 2016
Venetoclax Adds a New Arrow Targeting Relapsed CLL to the QuiverKerry A Rogers, John C Byrd
Blood|June 2, 2022
A CAPTIVATE-ing new regimen for CLLKerry A Rogers, Jennifer A Woyach
Hematology. American Society of Hematology. Education Program|December 7, 2024
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?Kerry A Rogers, Jennifer A Woyach
Seminars in Oncology|April 5, 2016
Secondary autoimmune cytopenias in chronic lymphocytic leukemiaKerry A Rogers, Jennifer A Woyach
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
Clinical Advances in Hematology & Oncology : H&O|January 17, 2025
Choosing between CAR T-cell therapy and pirtobrutinib in double-refractory CLLKerry A Rogers
The Lancet. Oncology|May 31, 2024
GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemiaKerry A Rogers
Blood|November 24, 2018
Is less equal with ibrutinib dose?Kerry A Rogers
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2023
A CAPTIVATEing Analysis for Higher-Risk CLLKerry A Rogers
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2020
Collectively Answering the Venetoclax BTK Inhibitor Sequencing Question in CLLKerry A Rogers
Leukemia & Lymphoma|March 18, 2024
Pairing obinutuzumab with venetoclax in relapsed CLLKerry A Rogers, Philip A Thompson
Cancer Cell|January 15, 2016
Venetoclax Adds a New Arrow Targeting Relapsed CLL to the QuiverKerry A Rogers, John C Byrd
Blood|June 2, 2022
A CAPTIVATE-ing new regimen for CLLKerry A Rogers, Jennifer A Woyach
Hematology. American Society of Hematology. Education Program|December 7, 2024
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?Kerry A Rogers, Jennifer A Woyach
Seminars in Oncology|April 5, 2016
Secondary autoimmune cytopenias in chronic lymphocytic leukemiaKerry A Rogers, Jennifer A Woyach
Pageof 10